Elevated serum ferritin contributes to treatment-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). The multicenter DE02 trial assessed the safety, efficacy and impact of deferasirox on iron homeostasis after allogeneic HSCT. Deferasirox was administered at a starting dose of 10 mg/kg per day to 76 recipients of allogeneic HSCT, with subsequent dose adjustments based on efficacy and safety. Deferasirox was initiated at a median of 168 days after HSCT, with 84% of patients still on immunosuppression. Baseline serum ferritin declined from 2045 to 957 ng/mL. Deferasirox induced a negative iron balance in 84% of patients. Hemoglobin increased in the first 3 months, and trough serum cyclosporine levels were stable. Median exposure was 330 days, with a median compliance rate of 480%. The most common investigator-reported drug-related adverse events (AEs) were increased blood creatinine (26.5%), nausea (9.0%) and abdominal discomfort (8.3%). Fifty-four (71.1%) patients experienced drug-related AEs, which occasionally resulted in discontinuation (gastrointestinal (n = 6), skin (n = 3), elevated transaminases (n = 1) and creatinine (n = 1)). The incidence of AEs appeared to be dose related, with 7.5 mg/kg per day being the best-tolerated dose. Low-dose deferasirox is an effective chelation therapy after allogeneic HSCT, with a manageable safety profile, even in patients receiving cyclosporine.
INTRODUCTION
The exposure of patients with hematologic disorders to RBC transfusions makes them susceptible to iron overload. 1 Thus, it is not surprising that elevated serum ferritin (SF) is commonly found after allogeneic hematopoietic stem cell transplantation (HSCT). 2 No physiologic mechanism for iron excretion exists in humans and excess iron could persist for years after HSCT. [2] [3] [4] [5] Additionally, iron homeostasis is frequently complicated by factors known to modulate hepcidin expression such as ineffective erythropoiesis, inflammation, infections and hypoxia. 6 The negative impact of hyperferritinemia on survival after allogeneic HSCT is well recognized, 1, 2, 7, 8 hepatic dysfunction may be exacerbated [9] [10] [11] and pre-HSCT iron chelation may be associated with improved survival and reduced non-relapse mortality. 13 Data suggest that post-HSCT SF is comparable to pre-HSCT values, 12 and hyperferritinemia up to day +720 post HSCT could significantly be associated with decreased survival. 8 Hence, lowering ferritin after HSCT through phlebotomy 10, [14] [15] [16] [17] and/or iron chelation 15, [17] [18] [19] [20] [21] seems rational, although the impact on survival is not yet known and needs to be studied in controlled trials.
Deferasirox is an oral iron chelator for patients with iron overload. [22] [23] [24] [25] [26] [27] [28] However, data regarding the use of deferasirox after allogeneic HSCT are limited. 15, 17, 19, 20 This prospective multicenter trial is, to the best of our knowledge, the largest trial evaluating the efficacy and safety of deferasirox after allogeneic HSCT. The impact on cyclosporine absorption as well as surrogate markers of iron stores and hepcidin dynamics were analyzed.
MATERIALS AND METHODS
Additional methods can be found in the Supplementary Information.
Patients
Eligible patients were ⩾ 18 years with transfusional hyperferritinemia (⩾20 RBC units or 100 mL/kg prepacked RBCs and an SF 41000 ng/mL), 3-12 months after allogeneic HSCT with adequate engraftment, a neutrophil count 41000/mm 3 and no active inflammation (C-reactive protein o10 mg/L). Major exclusion criteria were: alanine aminotransferase (ALT) 45 × upper limit of normal (ULN), serum creatinine 41.5 × ULN, creatinine clearance o60 mL/min, nephrotic syndrome, clinically relevant ocular or auditory toxicity and active GvHD.
Study design
This was a 1-year prospective, single-arm, open-label multicenter study. Following a 14-day screening phase, patients were administered deferasirox over 52 weeks starting with 10 mg/kg per day. In the absence of adverse events (AEs), a stepwise escalation of 5 mg/kg per day every 2 weeks to a maximum of 20 mg/kg per day by the end of week 4 was allowed. This dose was maintained until study completion or ferritin reached ⩽ 500 ng/mL, whichever occurred first. The rationale for the gradual escalation was tolerability as some of the dose-dependent AEs of deferasirox are frequently encountered in patients after HSCT. Dose was adjusted based on safety and efficacy markers; the dose reduced by 10 mg/kg per day if creatinine increased by 433% from baseline or was 1.5 × ULN or interrupted if any toxicity occurred ⩾ grade II according to the National Cancer Institute common toxicity criteria (version 3) or when ferritin reached o500ng/mL. Deferasirox was interrupted if transaminase levels were 45×ULN and could not be attributed to other causes. Audiometry and ophthalmologic examinations were obligatory before and at the end of study, as well as if symptoms occurred. Notable auditory (decreased hearing) and ocular (lens opacities) disturbances that seemed to be connected to deferasirox mandated a permanent drug discontinuation.
The study was conducted in accordance with the Good Clinical Practice guidelines and ethical standards in the Declaration of Helsinki. All patients provided written informed consent.
Assessments
The primary objective was the efficacy of deferasirox after allogeneic HSCT (irrespective of conditioning regimen) by comparing SF at baseline and week 52. Secondary objectives were: the relationship between ferritin, transferrin and transferrin saturation; the influence of deferasirox on cyclosporine absorption; and to evaluate hepcidin under chelation. Assessments are detailed within the Supplementary Information. Safety was assessed by reported AEs, laboratory parameters and clinical evaluations.
Statistical methods
The primary population was the intent-to-treat (ITT) population (sample size calculation is provided in the Supplementary Information). For missing values, last observation carried forward principles were applied. Summary statistics for ferritin change from baseline were provided by visit, with 95% confidence intervals (CIs) tested using a paired t-test with a 0.05 two-sided significance level. Wilcoxon's signed-rank test was also applied. Secondary variables were analyzed in an exploratory manner for the intent-to-treat and completer (intent-to-treat patients who completed the study) populations. Correlations were analyzed using Pearson's correlation coefficient. Treatment response was dichotomized as patients with 410% SF reduction from baseline versus patients with ⩽ 10% reduction. A logistic regression model was used with the following covariates: number of blood transfusions since diagnosis, number of days exposed to study drug, HFE genotype after HSCT and hepcidin change from baseline. Odds ratios together with CIs and parameter estimates were reported.
RESULTS

Patient disposition and baseline demographics
Between 24 April 2008 and 29 June 2012, 82 patients were screened, 76 were recruited and 46 completed the study (Figure 1 ). Baseline characteristics are summarized in Table 1 . Median age was 56 years. AML was the major indication for HSCT. Median number of RBC transfusions before study entry was 37 U. The median (range) baseline SF was 2045 ng/mL (772-7773); baseline ferritin was 42000 ng/mL in 43 (56.5%) patients. Ferritin correlated with the transfusional burden (P = 0.01). Transferrin was below the lower normal limit of 1.9 g/L in 66.7% and transferrin saturation was above the ULN of 45% in 58% of patients. Median urinary hepcidin was 1.2 nmol/mmol creatinine (normal reference range 0.01-10.6 nmol/mmol creatinine 29 ). HFE genotyping after HSCT (n = 67) revealed an HFE mutation in 27 (40.3%) patients. Deferasirox was started after HSCT at a median (range) of 168 days (92-363), with 64 (84.2%) patients still on immunosuppression including 54 patients receiving cyclosporine.
Exposure to deferasirox The median starting dose was 625 mg (10 mg/kg per day). The median (range) duration of exposure was 330.5 days (15-376 days) with a median daily dose of 504 mg, which corresponds to 7.5 mg/kg per day. Compliance 480% was reported in 58 (88%) of 66 assessable patients. Compliance was assessed by the Dosage Administration Case Report Form where dispensed, used and unused pills were captured, as well as the information provided by patients in a study drug diary. In the intent-to-treat population an average dose of 500 mg per day was reached by week 11 and maintained until the end of the trial. Deferasirox for the treatment of hyperferritinemia after HSCT N Jaekel et al Chelation Over time, a steady decline in SF was observed; median ferritin was 957 ng/mL at the end of the trial, representing a 53% reduction from baseline (median change, -812 ng/mL; 95% CI: -612, -1216; P o0.0001; Figure 2) . A 410% reduction occurred in 84% of patients irrespective of previous transfusions (P = 0.6), HFE genotype (P = 0.7) or interval between HSCT and chelation (P = 0.8). A longer deferasirox exposure time was associated with improved chelation (P = 0.02) irrespective of baseline ferritin. Patients with baseline ferritin ⩾ 2000 ng/mL (n = 43) had a median ferritin reduction of 46%.
Transferrin saturation declined to a median (range) of 44% (15.5-99%) at the last evaluation and correlated with ferritin (r = 0.6; P o0.0001). A rise in transferrin to a median (range) of 2 g/L (1.0-3.1) was observed, which was associated with the decline in ferritin (r = -0.6; P o 0.0001).
In the first weeks, an early and fluctuating upsurge in transferrin and transferrin saturation occurred that was maintained for the first 5-6 months, followed by a steady increase in transferrin and decline in transferrin saturation (Figure 2 ). Hepcidin levels behaved analogously with a fourfold amplification peaking at week 13 and a subsequent return to near baseline values over the subsequent months (Figure 3) .
Hemoglobin values under deferasirox Baseline median hemoglobin (Hb) was 111 g/L; values were below the lower normal limit for sex in 64 (84%) patients. Only 14 (18.4%) patients were transfusion-dependent at baseline. The decline in ferritin was accompanied by an improvement in Hb (Figure 4a) , with a return to normal values in 23 (36%) patients with baseline anemia. At the end of the trial, median (range) Hb was 127 g/L (48-156). Actually, 63% of the total upsurge in Hb occurred by week 13 (Figure 4b ).
Deferasirox and concomitant cyclosporine
In the first 20 patients, trough serum cyclosporine level (TSCL) was measured at baseline and three times weekly over an 8-week period; during this time patients received a median (range) deferasirox of 1000 mg per day (375-1750). Median (range) TSCL at baseline was 68 ng/mL (10-181). Irrespective of deferasirox dose applied, no significant alterations in TSCL were observed over time (weeks 1 and 2: median 84 ng/mL; weeks 3 and 4: median 72 ng/mL; weeks 4-8: median 60 ng/mL). For each individual patient, TSCL was maintained at a level considered adequate by the treating physician and no superfluous cyclosporine dose adjustments were required. In all subsequent patients, TSCL was monitored once weekly during the first 4 weeks under deferasirox.
The initial results were confirmed in the entire study population (Supplementary Figure 1) .
Deferasirox and chronic GvHD
Chronic GvHD was documented in 34 (44.7%) patients while on study drug. GvHD was limited in 27 (79%) and extensive in seven (21%) patients. Deferasirox was discontinued in one patient because of GvHD.
Safety and tolerability Irrespective of their relationship to study drug, 892 AEs were documented in 76 (100%) patients, the majority of which were mild (53.6%) or moderate (38.3%) in intensity.
Most common investigator-reported AEs were increased creatinine (n = 41, 53.9%), nausea (n = 32, 42.1%) and vomiting (n = 30, 39.5%; Table 2 ). GvHD was reported as an AE in 14 patients (18.4%).
Fifty-four (71.1%) patients were considered by the investigator to have experienced drug-related AEs, of which 61% were mild and 36% moderate in severity. Severe drug-related AEs were reported four times, which constituted 3% of deferasirox-related AEs (diarrhea; elevation in ALT/aspartate aminotransferase, skin rash and GvHD). The most common drug-related AEs were increased creatinine (26.5%), nausea (9.0%) and abdominal discomfort (8.3%; Figure 5 ). The incidence of hematologic AEs was low (thrombocytopenia, 5.5%; neutropenia, 2.3%; and leucopenia, 1.6%). Two (2.6%) fatal infections occurred during the study, neither of which were considered to be related to deferasirox. No discontinuation occurred because of auditory or ocular disturbances.
Deferasirox reductions and/or temporary interruption because of AEs were required in 65 patients (85.5%; Supplementary Table 1 ) mainly because of creatinine elevation, gastrointestinal (GI) disorders, infections, elevation in ALT/aspartate aminotransferase, GvHD and skin rash. Deferasirox was discontinued in one patient because of active GvHD of the liver. The most common non-hematologic reasons for stopping deferasirox were GI-related Figure 5 . Frequency of the most common investigator-reported drug-related AEs.
Deferasirox for the treatment of hyperferritinemia after HSCT N Jaekel et al AEs (n = 6 (7.9%)), skin rash and infections (n = 3 each (3.9%)). Deferasirox was permanently discontinued because of relapse of hematologic disease in eight (10.5%) patients. Although creatinine elevation was the most frequent laboratory abnormality and the main reason for dose modification and/or temporary interruption of deferasirox, it led to permanent discontinuation in only one patient. For all safety measurements, the maximum creatinine elevations from baseline were grade I in 44 (58%) and grade II in 23 (30%) patients. Median (range) creatinine was 85 μmol/L (39-165) at baseline and 97.5 μmol/L (48-152) at the end of study. Similarly, while elevation in aspartate aminotransferase and ALT led to dose modification and/or temporary interruption of deferasirox in 10 (13.2%) patients, it led to discontinuation in only one patient. Grade III aspartate aminotransferase levels were documented five times; ALT values 4grade II were measured nine times. However, ALT levels normalized under deferasirox in 19 (57.6%) out of 33 patients with abnormal baseline values.
DISCUSSION
In accordance with a smaller prospective trial (n = 30), 30 our data indicate that management of hyperferritinemia with deferasirox can be accomplished after HSCT in adult non-thalassemic patients. Although our cohort included many patients with baseline ferritin 42000 ng/mL, a negative iron balance was achieved with o10 mg/kg per day deferasirox. This is explained by the fact that, unlike other patients with transfusion-dependent anemias, patients after allogeneic HSCT comprise a unique group in whom the cause of hyperferritinemia, namely the underlying disease, has been abrogated by transplantation. This allows the investigation of iron homeostasis under chelation without ongoing transfusions.
The low transferrin and high transferrin baseline saturations are typical for patients with iron overload. Upon initiation of deferasirox, iron is mobilized rapidly from tissues, released into the circulation and bound to transferrin; this may explain the early upsurge in transferrin and transferrin saturation. The simultaneous fourfold amplification of hepcidin may be a compensatory mechanism counteracting the rapid mobilization of tissue iron. The liver-derived peptide hepcidin is upregulated in response to iron, which prevents further iron absorption and release from macrophages by consequent degradation of ferroportin. 6, 31 The early upregulation of hepcidin might protect the parenchyma by preventing increased ferroportin-mediated iron export from macrophages. With continuous chelation, a steady decline in transferrin saturation accompanied by a gradual decline in ferritin leads to the downregulation of hepcidin, thus permitting further iron mobilization from tissues.
Hepcidin concentration in plasma and urine differ widely depending on the mass spectrometry and immunochemical methods used. There is no standard method and all are considered acceptable including the mass spectrometry-based method used here (Supplementary Methods). 32 Nevertheless, the availability of different methods hinders comparing data.
HFE mutations, which account for most but not all cases of hemochromatosis, have been associated with a reduction of liver hepcidin expression. [33] [34] [35] After allogeneic HSCT, the HFE genotype likely reflects donor rather than patient genotype. 16 The 40% incidence of HFE mutations is in accordance with the prevalence in populations of European descent. 36 There was no association between HFE genotype and changes in SF under deferasirox; this may be because of the low penetrance of HFE mutations, the high incidence of heterozygote H63D mutation with as yet uncertain pathogenic significance and the fact that HFE genotype of the recipient hepatocyte, and not the donor macrophage, has the key role in iron metabolism. 37, 38 The early improvement in Hb under deferasirox is comparable to that described in patients with MDS and may be because of improved hematopoiesis. 39, 40 It has been shown that chelation with deferasirox leads to rapid reduction of the deleterious labile plasma iron, thereby ameliorating the damage caused by reactive oxygen species within RBCs. 41, 42 The improvement in hematopoiesis under chelation reduces the inhibitory effect of suppressed erythropoiesis on hepcidin and thus may, at least partially, explain the early upsurge in urinary hepcidin similar to that observed in MDS. 43 The comparable upsurge in Hb under late post-HSCT phlebotomy started after a median of 18 months supports the view of improved hematopoiesis via iron removal. 16 Taken together, these data indicate that suppressed erythropoiesis frequently seen after HSCT may partly be attributable to, or accentuated by, iron and/or oxidative stress.
Cyclosporine is metabolized in the liver via cytochrome P450 (CYP)3A4. Deferasirox induces CYP3A4 and may decrease the serum concentration of CYP3A4 substrates. 44 However, it was not known whether a relevant deferasirox-cyclosporine interaction exists. In this trial, TSCLs were monitored frequently. We can conclude that maintaining adequate cyclosporine levels is not complicated by concomitant deferasirox treatment.
AEs were frequent, although most were mild to moderate and transient. This is similar to the data reported by Vallejo et al. 30 As expected, the most frequent deferasirox-related AEs in this trial were similar to what is already known. [22] [23] [24] 27, 45, 46 In the EPIC (European Prospective Investigation into Cancer and Nutrition) trial for MDS, AEs were responsible for a discontinuation rate of 23%, many of which were renal or GI events (overall discontinuation rate 49%). 22, 24 Further, deferasirox treatment is envisaged to be difficult after HSCT as GI, liver and skin AEs could mimic and/or exacerbate GvHD-associated abnormalities. The incidence of GvHD in this trial was similar to published series without chelation. 47, 48 Of note is that the Glucksberg/Shulman criteria used for GvHD classification in this trial have now largely been replaced by the National Institutes of Health Consensus Conference proposals. [49] [50] [51] [52] Overall, deferasirox dose reduction and/or temporary interruption were required in the majority of patients. Creatinine elevation was the most frequent laboratory abnormality and the main reason for dose modification and/or temporary interruption. All creatinine increases from baseline were ⩽ grade II because of the strict safety requirement for dose reductions following minimal creatinine changes, even if within normal ranges. The improvement in liver enzymes under deferasirox is similar to that observed under phlebotomy. 16 Chronic liver disease after HSCT is common, with iron overload being one of the most frequent causes. [9] [10] [11] Besides iron chelation, phlebotomy is another safe, convenient and cost-effective option. 10, [14] [15] [16] [17] Yet, data on phlebotomy are hitherto limited. One restriction is that phlebotomy could not be initiated early after HSCT in every patient, which might hamper its value as an instrument to improve outcome assuming that the impact of elevated ferritin on outcome might be clearest early on after HSCT (although this needs to be proved). The current trial provides data regarding the practicability and safety of iron chelation with low-dose deferasirox as an additional option in the transplant setting. This study does not support the superiority of chelation over phlebotomy in those patients who would tolerate the latter. Only controlled trials comparing phlebotomy with medical chelation could provide answers.
In a meta-analysis, SF 41000 ng/mL has been identified as a significant risk factor for survival after HSCT. 53 Nevertheless, it needs to be remembered that ferritin is an acceptable but imperfect surrogate of true iron overload. In contrast to SF, the association between iron overload as assessed by liver iron content by magnetic resonance imaging and survival after HSCT is still controversial. 53 Thus, the adverse prognosis of SF might be related to other not yet well-studied pathologies such as labile plasma iron.
Finally and most importantly, the impact of lowering ferritin after HSCT on survival is not yet known and requires creative, controlled and randomized next-generation trials with meticulous measurement of organ functions and long-term follow-up. 
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